Inari Medical Inc

Inari Medical — Investor Day (September 2022)

99 slides from Inari Medical's investor day presentation, Sep 20, 2022

  1. Slide 1: 2022 Inari Medical Investor Day

    Exhibit 99.1 2022 Inari Medical Investor Day Sandy | Boynton Beach, FL

  2. Slide 2: Financial Information and Forward Looking Statements

    Financial Information Unless otherwise indicated, all financial and operational information included herein is as of June 30, 2022. Indications for Use and Publication References Indications for Use and relevant labeling information for all Inari products included in this presentation are included i

  3. Slide 3: Opening Remarks

    Opening Remarks Bill Hoffman, CEO Amanda | Louisville , KY

  4. Slide 4: Our dedication to changing lives drives every decision we make

    Our dedication to changing lives drives every decision we make Amanda | Louisville , KY Jessica, 44 | Valparaiso, IN

  5. Slide 5: Patients first values

    We’ve made Patients first. Make no small plans. improving lives our Always. Ever. responsibility. And that drives our passion and success Take care of each other. Constantly.

  6. Slide 6: Introduction To Inari

    Introduction To Inari Drew Hykes, COO Audry | Detroit, MI

  7. Slide 7: Management Presentation Agenda

    Management Presentation Agenda Time Duration Session 9:00 – 9:20AM 20 min. Introduction 9:20 – 10:10 AM 50 min. Inari Five Growth Drivers 10:10 – 10:20 AM 10 min. Break 10:20 – 10:40 AM 20 min. Physician Panel 10:40 – 10:50 AM 10 min. Financials and Closing Remarks 10:50 – 11:30 AM 40 min. Q&A

  8. Slide 8: Strong leadership team with breadth & depth

    Strong leadership team with breadth & depth Bill Hoffman Mitch Hill Drew Hykes Dr. Tom Tu Chief Executive Officer Chief Financial Officer Chief Operating Officer Chief Medical Officer Angela Ahmad Brian Strauss Eric Louw Janet Byk John Borrell Justin Crockett Kevin Strange Kit Cariquitan Eric Khairy

  9. Slide 9: Venous Thromboembolism (VTE)

    Venous Thromboembolism (VTE) DVT Up to Develop Post-Thrombotic Syndrome (PTS) within 2 years of a proximal DVT 50% PE Leading cause of cardiovascular death #3

  10. Slide 10: VTE is a large and highly underpenetrated opportunity

    DVT PE 430,000 280,000 US Patients US Patients VTE is a large $3.0B $2.8B and highly TAM TAM underpenetrated Interventional Procedures Conservative Medical Management opportunity to serve patients $ in need 5.8B Total US VTE TAM Opportunity $ 15B+ Global VTE TAM Opportunity

  11. Slide 11: Treatment of VTE evolving to definitive mechanical catheter intervention

    Treatment of VTE evolving to definitive mechanical catheter intervention Myocardial Anti-Coagulation Definitive Catheter Lytics Based Only Therapy Infarction Anti-Coagulation Definitive Catheter Lytics Based Stroke Only Therapy Expected Path for Anti-Coagulation Definitive Catheter Lytics Based VTE

  12. Slide 12: Highly differentiated, purpose-built solutions

    Highly differentiated, purpose-built solutions Simple, intuitive solutions Near complete thrombus removal Eliminate need for dangerous lytics Minimal blood loss Favorable hospital economics

  13. Slide 13: Taking out all the clot matters

    Taking out all the clot matters

  14. Slide 14: Our five growth drivers remain the roadmap

    Our five growth drivers remain the roadmap Innovating Expanding Our Driving Deeper Building Clinical Expanding Into Purpose-Built 1 2 3 4 5 U.S. Sales Force VTE Penetration Evidence New Markets Solutions >$20B Total Global TAM 270+ <5% 250+ 5 + U.S. Sales Territories Penetration into U.S. VTE Peer R

  15. Slide 15: Consistent, premium financial performance

    Annual Revenue ($ in Millions) $300 Consistent, $250 133% premium $200 CAGR financial $150 $100 performance $50 $0 2019 2020 2021 $277M 91% 98% $330M 2021 Total Revenue 2021 Gross Margin YOY Growth (From FY20) Cash, Cash Equivalents, & Short-Term Investments (Q2 2022)

  16. Slide 16: Our core competencies are scalable

    Our core competencies are scalable and allow us to treat more patients Identify major unmet R&D innovation engine to High-Touch, scalable Clinical infrastructure patient needs rapidly design purpose- commercial org & market generating data to change built devices development capabilities standard of

  17. Slide 17: No small plans. And we're just getting started

    No small plans. And we’re just getting started EXPANDING US SALES FORCE BUILDING THE LARGEST INTERVENTIONAL SALES FORCE 1 DRIVING DEEPER PENETRATION STANDARDIZING PATIENT PATHWAYS 2 BUILDING CLINICAL EVIDENCE EXECUTING GUIDELINE-CHANGING CLINICAL TRIALS 3 INNOVATING NEW PRODUCTS DEVELOPING PURPOSE-B

  18. Slide 18: Growth Driver: Expanding Our US Sales Force

    Growth Driver 1 Expanding Our US Sales Force John Borrell, SVP Sales

  19. Slide 19: Sales territories and active accounts growth

    2020 (Q2) 2022 (YTD) Sales >3.5x ~75 >270 Significant Territories (US) growth in sales territories, Active increasing >2x ~650 ~1,400 Accounts (US) density of coverage Accounts per 0.6x ~9 ~5 Territory

  20. Slide 20: Productivity remains high despite growth and territory splits

    PRODUCTIVITY REMAINS HIGH DESPITE GROWTH AND AGGRESSIVE TERRITORY SPLITS 350 100 90 300 80 Revenue Growth Focused on 250 70 60 growth but 3.6x 200 50 3.1x remaining 150 40 Number of Territories efficient 30 100 20 50 10 0 0

  21. Slide 21: Average sales rep productivity over first months

    AVERAGE SALES REP PRODUCTIVITY OVER FIRST 18 MONTHS 20 2.5X Sales rep 18 16 productivity 14 12 ramps up 10 8 quickly after 6 start date 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Months After Start Cases Per Territory

  22. Slide 22: Continuing growth to fully tackle VTE and address new disease states

    Continuing growth to fully tackle VTE and address new disease states 2022 FUTURE STATE Potential to be the largest interventionally- >270 focused sales team US Sales Territories

  23. Slide 23: Commercial / market development team

    COMMERCIAL / MARKET DEVELOPMENT TEAM 12 8 National Health Economics & Accounts Market Access (HEMA) Sales team efforts amplified by robust non-sales 7 7 Inari Solutions Medical Affairs commercial team Groups (ISG) (including doctors) 8 34 Medical Upstream/Downstream Education Group Marketing & Sales

  24. Slide 24: Intentional fit-based hiring and promotion from within

    Intentional fit-based hiring and promotion from within Single-tier sales team w/ ~90% case High-powered, high- presence touch commercial Mining information across all sources, informing every decision we make system designed to solve patient needs Solution-based toolkits, not widgets Deliberate terr

  25. Slide 25: Our commercial system enables us to scale in new markets

    Our commercial system enables us to scale in new markets with significant unmet needs US VTE Global Leadership Inari High-Touch Commercial Global Markets Solving Patient System Unmet Needs New Large Unmet Needs

  26. Slide 26: Growth Driver: Driving Deeper Penetration

    Growth Driver 2 Driving Deeper Penetration Eric Khairy, SVP Marketing

  27. Slide 27: A significant responsibility

    A significant responsibility Addressable US VTE ~710,000 patients per year

  28. Slide 28: A significant responsibility

    A significant responsibility 15-20% Receive any intervention Addressable US VTE ~710,000 patients per year

  29. Slide 29: A significant responsibility

    A significant responsibility 15-20% Receive any intervention <5% Treated with Inari products today Addressable US VTE ~710,000 patients per year

  30. Slide 30: VTE lacks a systematic approach to identify, screen, and triage patients

    VTE lacks a systematic approach to identify, screen, and triage patients MYOCARDIAL STROKE VTE INFARCTION Consistent screening Consistent screening protocols protocols Algorithms for triage Algorithms for triage and treatment and treatment Tracked metrics Tracked metrics Interventionalist Interventi

  31. Slide 31: VTE patients are inside the hospital, yet most never see a VTE expert

    VTE patients are inside the hospital, yet most never see a VTE expert Annual US VTE Incidence 710K US Hospital Beds ~740K Annual US Incidence per Bed ~1 500 Bed ~500 = Mid-sized hospital addressable VTE patients/year

  32. Slide 32: Helping hospitals build programs that connect VTE patients to experts

    We’re helping Excellent clinical outcomes hospitals build programs that Positive hospital economics connect VTE Systematic patient pathway patients to VTE (i.e., a “VTE program”) experts

  33. Slide 33: VTE Excellence is a codified & scalable process

    VTE Excellence is a codified & scalable process to build VTE programs ENGAGE EMPOWER EXCEL ~120 Inari accounts ~20 Inari accounts ~1,250 Inari accounts Solidify consistent patient Find champions, Create patient pathway identification, triage, build the foundation and build awareness tracking

  34. Slide 34: Account-level TAM penetration by stage

    APPROX. ACCOUNT-LEVEL TAM PENETRATION BY STAGE 4x VTE Excellence activities are 22% beginning to drive deeper 16% account-level TAM penetration 5% Engage Empower Excel

  35. Slide 35: What's the future? Interventional TAM penetration in context

    What’s the future? Interventional TAM penetration in context Myocardial VTE Today Infarction ~90% 15-20% Interventional TAM Interventional TAM penetration* penetration *Intervention includes both CABG and angioplasty

  36. Slide 36: Growth Driver: Building Clinical Evidence

    Growth Driver 3 Building Clinical Evidence Tara Dunn, SVP Clinical Affairs Larry | Newport Beach, CA

  37. Slide 37: Transforming patient care

    Transforming patient care Do the right thing Generate data Develop Set the for patients with urgency the market bar high

  38. Slide 38: Clinical by the numbers

    Clinical by the numbers 2,000+ 250+ Patients studied Peer reviewed to date publications INCLUDING 2 RCTS 6 20+ Major prospective Active or completed Studies IIR engagements

  39. Slide 39: Strong and versatile clinical team

    Strong and versatile team driving the quality and pace of best-in-class evidence generation Clinical Clinical Biostats Scientific Insights Research Communication Real World Data Trial Clinical Data Dissemination Execution Analytics

  40. Slide 40: A tsunami of clinical data

    A tsunami of clinical data PE Trials: FLASH interim RCT enrollment FLASH 800 FlowTriever Real-world all- late-breaking begins late-breaking System comers PE registry clinical trial clinical trial enrollment begins IDE enrollment begins High-risk PE Interim First high-risk st EU enrollment 1 mechanic

  41. Slide 41: Setting a high bar for VTE evidence

    Setting a high bar for VTE evidence PE STUDIES DVT STUDIES First Industry Sponsored Largest Prospective PE Largest Prospective First Inari RCT Largest Prospective DVT DVT RCT Device Study High-risk PE Device Study (FlowTriever v. CDT in PE) Thrombectomy Study (ClotTriever v. AC) ~1,000 Patients | 83

  42. Slide 42: FLASH is the largest prospective registry in PE

    FLASH is the largest prospective registry in PE with exceptional results EXCELLENT IMMEDIATE LASTING PATIENT MORTALITY SAFETY PATIENT RELIEF BENEFITS FlowTriever® Mean Pulmonary System 10.2% Artery Pressure PERT Consortium -7.4 1.5% 0% mmHg Post-PE Syndrome Device related MAEs 1.3% All-Cause Mortali

  43. Slide 43: FLAME: Changing guidelines for high-risk PE

    FLAME: High-risk PE guidelines are from an 8 patient study. FLAME is 100+ patients Changing Guidelines Designed per AHA recommendations Doing What's Right Up to 50% of high-risk patients die within 100+ Patients 30 days 11 Sites Developing the Market Why not treat intermediate-risk?

  44. Slide 44: PEERLESS: Superiority RCT of FlowTriever vs CDT

    HIGHLIGHTS PEERLESS: Superiority Currently >60% of patients RCT of FlowTriever vs intervened on receive Catheter CDT in PE Directed Thrombolysis (CDT) Primary endpoint via win ratio: Intermediate-High Risk PE • All-Cause Mortality • Intracranial Hemorrhage • ISTH Major Bleeding Up to 150 Patients 55

  45. Slide 45: CLOUT demonstrates we can do better for DVT patients

    EXCELLENT SAFETY CLOUT demonstrates 0% we can do better Vessel/Valve for DVT patients Damage ON-TABLE EFFECTIVENESS 86% 500 47 Effectiveness in Core Lab Patients Enrolled Sites Adjudicated Clot Removal LASTING PATIENT BENEFITS 2 out of 3 91% With Subacute and/or Chronic Clot Freedom from Moderate to

  46. Slide 46: DEFIANCE: Superiority RCT of ClotTriever vs Anticoagulation

    HIGHLIGHTS DEFIANCE: Superiority RCT of ClotTriever vs First global industry- sponsored RCT for DVT Anticoagulation in DVT Primary endpoint via win ratio: • Treatment failure or escalation Moderate-Severe Iliofemoral DVT of therapy • Post-Thrombotic Syndrome severity at 6 months 300 Patients Randomi

  47. Slide 47: Exceptional program productivity and quality

    Exceptional program Enrollment began 2022 productivity and quality of patient outcomes Enrollment begins 2023 2021 Registry Expansion 1,000+ 2018 2018 2020 Global Definitive 2016 RCTs Global Studies US Real-Word Registries IDE

  48. Slide 48: Growth Driver: Innovating New Products

    Growth Driver 4 Innovating New Products Dr. Tom Tu, CMO

  49. Slide 49: Years of knowledge and commitment

    Years of knowledge and commitment. Our mission to address unmet needs Protrieve Triever 24 Triever 20 Curve st 1 Gen FlowTriever st 1 Gen FlowTriever Triever 24 Flex ClotTriever XL Disks Artix FlowSaver 2015 2016 2017 2018 2019 2020 2021 2022 Intri24 InThrill FT 2 LBS 2 T20 Large Bore Syringe (LBS)

  50. Slide 50: Our Innovation Engine implements purpose-built solutions

    Our Innovation Engine continues to implement purpose-built solutions for unmet patient needs Rapid innovation “Engine Room” A Scalable, via in house machine shop, R&D infrastructure Repeatable System 3D-printing, bio-skills lab, laser cutting, etc. A Scalable, Repeatable 80 Full Time Engineers +9 Up

  51. Slide 51: Large bore catheters produce large clot hauls

    Large bore catheters produce large clot hauls

  52. Slide 52: A comprehensive PE procedure solution

    A comprehensive PE procedure solution years in the making Safely, Quickly Track Large Clot Hauls Address Challenging Minimal Blood Loss Throughthe Heart Without Lytics Clot or Anatomy Large Bore Fourth Generation Triever20 Curve® FlowSaver® Blood Aspiration Triever Catheters Catheter Return System I

  53. Slide 53: A purpose-built DVT treatment for full range of clot chronicity

    A purpose-built DVT treatment for the full range of clot chronicity Coring Element Collection Basket

  54. Slide 54: A comprehensive DVT procedure solution

    A comprehensive DVT procedure solution years in the making Access Acute to Chronic Clot Removal Complex Procedures ClotTriever Gen 3 ClotTriever 13 Gen 3 ProTrieve™ Catheter Sheath Sheath ClotTriever 16 Gen 3 ClotTriever BOLD FlowTriever Sheaths Catheter Disk Catheters

  55. Slide 55: Protrieve provides confidence during complex DVT and IVC procedures

    TM Protrieve provides confidence during complex DVT and IVC procedures 20F sheath designed for right IJ access and optimal positioning within the IVC Wall apposing funnel designed to trap emboli Compatible with ClotTriever and FlowTriever platforms 34mm self-expanding nitinol mesh funnel allows full

  56. Slide 56: Expanding beyond VTE to develop purpose-built solutions

    Expanding beyond VTE to develop purpose-built solutions for new diseases VTE LEADERSHIP BROADER PERIPHERAL SOLUTIONS TM TM Artix Chronic Venous InThrill ClotTriever FlowTriever System Disease System System System Toolkit

  57. Slide 57: Chronic Venous Disease (CVD)

    CVD often progresses from DVT and includes scarred Chronic Venous vein walls & wall-adherent obstructions Disease (CVD) Chronic clot Post-Thrombotic occlusions If obstructions are left unaddressed, patients can PTS and venous leg develop painful, ulcers (VLU) debilitating ulcers

  58. Slide 58: Conservative treatments for Chronic Venous Disease are inadequate

    Conservative treatments for Chronic Venous Disease are inadequate and only address symptoms Compression Therapy Anticoagulation <50% 1 in 5 VLUs healed at 12 weeks VLUs never heal

  59. Slide 59: ClotTriever BOLD designed for full range of clot chronicity

    ClotTriever BOLD was designed to extract the full range of clot chronicity Clot is often older than symptoms suggest ~30% greater radial force for improved wall apposition Improved thrombus engagement to treat the full range of acute to chronic DVT

  60. Slide 60: Building a solution-based toolkit for Chronic Venous Disease

    We’re building a solution-based toolkit to address Chronic Venous Disease Remove Acute to Chronic Cross Chronic Treat Chronic Treat Venous In-stent Venous Thrombus Venous Occlusions Venous Occlusions Chronic Re-thrombosis ClotTriever BOLD Catheter Stent Cleaner Crossing Recanalization Device(s) Devi

  61. Slide 61: Arterial Thromboembolism

    Arterial Thromboembolism Acute limb ischemia (ALI) Acute embolization event – extensive damage can happen if Acute visceral ischemia not treated quickly Chronic limb ischemia (CLI)

  62. Slide 62: Current treatments for arterial thromboembolism have drawbacks

    Often requires open surgical procedures Current treatments for Distal embolization and vessel trauma arterial thrombo- High rates of lytic use embolism have Significant blood loss significant drawbacks Need for a better, purpose-built solution

  63. Slide 63: The Artix System

    The Artix System: purpose-built toolkit for peripheral artery thromboembolism Artix MT Combines both aspiration and mechanical Device thrombectomy Sheath has 4X flow rate vs. existing arterial catheters Artix BG Balloon Guiding Sheath Proximal flow arrest to prevent distal embolization

  64. Slide 64: AV access thrombosis and small vessel thrombosis

    AV access thrombosis can result in complications and loss of access to Small Vessel life-saving dialysis Thrombosis Upper Extremity Below-the-knee AV thrombosis

  65. Slide 65: Limitations in current small vessel treatments

    AV “declotting” sends clot to the lungs, Limitations in exacerbating pulmonary hypertension current treatments High recurrence rates for small vessel Ineffective for chronic clot thrombosis Ineffective for large clot burdens Need for a better, purpose-built solution

  66. Slide 66: The InThrill System: a solution for smaller vessels

    The InThrill System: a solution for smaller vessels Self- expandable, laser-cut Effectively extracts clots element Addresses acute to chronic thrombus InThrill Catheter Tailor made for 4-10mm vessels InThrill Sheath Note: the InThrill device is indicated for use in the peripheral vasculature

  67. Slide 67: We're just getting started!

    We’re just getting started! ~ ~ 25+ 5K 70K Projects Across Cumulative Cumulative Current and Patients Patients New TAMs Treated Treated Protrieve T20 Curve Intri24 ClotTriever Gen 1-3 FlowTriever Gen 1-3 FlowStasis FlowSaver InThrill Future Purpose-Built Devices Coming FlowTriever Disks Triever16, 2

  68. Slide 68: Growth Driver: Expanding into New Markets

    Growth Driver 5 Expanding into New Markets Drew Hykes, COO

  69. Slide 69: Historically, two TAMs with two toolkits

    Historically, we have treated patients in two TAMs with two toolkits 2 PE + DVT TAMs

  70. Slide 70: Expanding into three new TAMs

    +3 TAMs Currently expanding into three Chronic Venous Disease new TAMs, Arterial Thromboembolism Small Vessel Thrombosis continuing to address large unmet needs 2 PE + DVT TAMs

  71. Slide 71: More purpose-built solutions to come

    +3 TAMs More purpose-built We have no solutions to come small plans. More purpose- Chronic Venous Disease built solutions Arterial Thromboembolism to come in Small Vessel Thrombosis incremental TAMs 2 PE + DVT TAMs

  72. Slide 72: Protrieve is a purpose-built solution for complex IVC cases

    Protrieve is a purpose-built solution for complex IVC cases LMR launched in August Enables complex IVC cases New tool for interventionalists treating DVT and PE $4K ASP affords incremental revenue

  73. Slide 73: Chronic Venous Disease prevalence opportunity

    CHRONIC ACUTE CHRONIC VENOUS THROMBUS THROMBUS DISEASE Chronic Venous Disease prevalence opportunity larger than core TAM INCIDENCE PREVALENCE ~ ~ ~ ~ 100K $1B 1M $10B Patients TAM Opportunity Patients TAM Opportunity

  74. Slide 74: Chronic Venous Disease: addressing the underlying cause

    Chronic Venous Disease: addressing the underlying cause via purpose-built devices ~3,000 CT-Bold cases Recanalization completed “Bold is amazing Device(s) for treating more-chronic In development ClotTriever BOLD Evaluating go-to-market options Launched Mar 2022* patients… but I CANNOT WAIT for what

  75. Slide 75: Arterial Thromboembolism large TAM

    Arterial • Acute event – extensive damage can happen if Thromboembolism not treated quickly large TAM with • Includes Acute Limb Ischemia, Acute Visceral significant unmet Ischemia, and CLI procedures where distal needs embolization occurs ~ ~ 80K $600M US Patient Incidence US TAM Opportunity

  76. Slide 76: Artix: toolkit for arterial thromboembolism

    Artix: purpose-built toolkit addressing unmet needs in arterial thromboembolism Artix MT LMR in April 2022; Balloon Sheath LMR in July 2022 No wonder “ lytics didn’t ` Significant site-of-service and physician work on that. overlap – Dr. Jerry Chung Targeting an ASP of ~$7.5K Additional tools in dev

  77. Slide 77: Small Vessel Thrombosis

    Small Vessel AV access Thrombosis: thrombosis can result in No purpose-built complications and loss of solutions exist for access to life- this large patient saving dialysis population ~ ~ ~ 150-200K 80K $1B US AVF thrombotic Addressable US BTK + UE Total US Market events / year thrombotic events /

  78. Slide 78: InThrill: novel solution for small vessels

    InThrill: a purpose-built, novel solution designed to treat small vessels LMR launched in August Targeting in-hospital procedures; significant treating physician overlap with DVT and PE We’v“ e been waiting a long Targeting an ASP of ~$4K time for a mechanical option like this that works. Additional

  79. Slide 79: Large US total addressable market across 5 disease states

    ~$ Pulmonary Embolism 2.8B Deep Vein ~$ Small Vessel 3.0B ~$ Thrombosis 1.0B Thrombosis Arterial Large US total ~$ 0.6B Thromboembolism addressable market totaling ~$ Chronic Venous 1.0B Disease ~$8B across 5 Incidence disease states Does not include ~$10B incremental prevalence opportunity

  80. Slide 80: Substantial global opportunity exists

    > $20B Substantial Global Incidence TAM global across 5 Disease States opportunity exists across VTE and three new disease ~ states $10B CVD Prevalence Opportunity (US only)

  81. Slide 81: Laying the foundation to treat patients globally

    Laying the foundation to treat patients globally Cases Completed Approval Received Approvals In-progress CASES COMPLETED IN 20+ COUNTRIES ACROSS THE GLOBE

  82. Slide 82: No small plans. And we're just getting started

    No small plans. And we’re just getting started EXPANDING US SALES FORCE BUILDING THE LARGEST INTERVENTIONAL SALES FORCE 1 DRIVING DEEPER PENETRATION STANDARDIZING PATIENT PATHWAYS 2 BUILDING CLINICAL EVIDENCE EXECUTING GUIDELINE-CHANGING CLINICAL TRIALS 3 INNOVATING NEW PRODUCTS DEVELOPING PURPOSE-B

  83. Slide 83: Break

    10 Minute Break

  84. Slide 84: Physician Panel

    Physician Panel Dr. Tom Tu, CMO

  85. Slide 85: Inari Investor Day Physician Panel Discussion

    Inari Investor Day Physician Panel Discussion Christopher M. Huff, MD Interventional Cardiology = OhioHealth Riverside Methodist Hospital Thomas Tu, MD Chief Medical Officer = Inari Medical Moderator Steven Abramowitz, MD Vascular Surgery = MedStar Washington Hospital Center

  86. Slide 86: Financials

    Financials Mitch Hill, CFO

  87. Slide 87: Proven track record of industry leading revenue growth

    We have a proven track record of industry leading revenue growth REVENUE (IN MILLIONS) +93% $360-$370 CAGR $277 $140 $51 2019 2020 2021 2022 (guidance) The reference to Inari 2022 revenue guidance is as of Q2 2022 earnings call, and is not being confirmed or updated herein.

  88. Slide 88: MedTech comps to approximate future VTE market size

    MedTech comps to approximate future VTE market size VTE PENETRATION TODAY INTERVENTIONAL PENETRATION PROXIES 15-20% Interventional Penetration Today ~30% ~90% $5.8B Myocardial Acute Ischemic TAM Infarction Stroke

  89. Slide 89: Substantial revenue opportunity for the leader

    Substantial revenue opportunity exists for the leader in $5.8B VTE TAM INARI REVENUE POTENTIAL 60% $1B+ $2B+ $1B+ 30% Inari 20% Today 30% 60% VTE Interventional Market Share (Procedures) VTE Interventional Penetration

  90. Slide 90: Premium growth combined with exceptional margin profile

    Premium growth combined with exceptional margin profile GROSS MARGIN 91.1% 90.6% 88.4% 88.7% 2019 2020 2021 2022(1H)

  91. Slide 91: Well-positioned for sustained operating profitability

    Well-positioned for sustained operating profitability 2022 2024+ Significant investment Sustained operating in our growth drivers profitability by 1H 2024 • Large, attractive market • Commercial team • ~85% target gross margin • Clinical research • Commercial productivity ramp • Product development

  92. Slide 92: All the components of a premium financial profile

    All the components of a premium financial profile Market leader in $5.8B underpenetrated US VTE market; expanding into global ~$20B+ TAM Exceptional gross margin profile Disciplined investments driving growth, operating leverage and consistent profitability Strong balance sheet and ~$330M cash posit

  93. Slide 93: Q&A

    Q&A

  94. Slide 94: Closing Remarks

    Closing Remarks

  95. Slide 95: Appendix

    Appendix

  96. Slide 96: Citations

    Citations Slide #: Source(s): 12 • Kahn, Susan R. Hematology Am Soc Hematol Educ Program. 2016 Dec 2; 2016(1): 413–418 12 • Pulmonary Embolism in 2017: Increasing Options for Increasing Incidence, National Center for Biotechnology Information, May 2017 • Hospital claims data 13, 17, 83 • Global Burd

  97. Slide 97: Device Indications For Use

    Device Indications For Use The FlowTriever System® is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels (2) injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. The FlowTriever System is intended for use in the periph

  98. Slide 98: Device Indications For Use (cont.)

    Device Indications For Use (cont.) TM The ClotTriever thrombectomy system consists of the ClotTriever catheter and ClotTrieversheath. The ClotTriever Thrombectomy System is indicated for: (1) the non-surgical removal of thrombi and emboli from blood vessels. (2) Injection, infusion, and/or aspiratio

  99. Slide 99: Device Indications For Use (cont.)

    Device Indications For Use (cont.) Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Refer to Instructions for Use for complete indications for use, contraindications, warnings, and precautions. All trademarks are property of their respective owners.

Inari Medical — Investor Day (September 2022) on 6ix